The epidemiology and clinical outcome of multiple myeloma in human immunodeficiency virus (HIV)-positive patients is poorly documented. There are uncertainties concerning the optimal management of this rare disorder. We report on the use of myeloablative chemotherapy with autologous stem cell transplantation in an HIV-positive patient with multiple myeloma.
Multiple myeloma has been rarely reported among HIV-positive patients. The diagnosis can be difficult, the clinical presentation is usually atypical and the course of the disease is often altered, with a bad prognosis. 2 We report the case of a patient with multiple myeloma and HIV infection, who was treated with high-dose chemotherapy and peripheral blood stem cell transplantation.
Case report
A 37-year-old homosexual man presented in August 1996 with fever of 1-month duration. He knew himself to be HIV positive since 1990. He had no other past medical history apart from anal condylomata. The CD4 + count was 300/mm 3 . He was treated with zidovudine (AZT: 300 mg twice daily) and dideoxycytosine (DDC: 0.75 mg three times daily). He complained of pain at the tip of the right scapula, in the right elbow and in the left side of the rib- cage. A MDPTc99m bone scintigram showed radioisotope uptake at the level of the right scapula, of both humeral heads, of five ribs, and a heterogeneous uptake in the skull and sternum. X-rays showed lytic bone lesions in the scapula and the 11th right rib. Computerized tomographyguided biopsy of the scapular lesion revealed an IgA kappa secreting plasmocytoma. Blood tests disclosed a macrocytic anemia. Creatinine, calcium and LDH were within normal values. Beta2-microglobulin was 3.1 mg/l. Monoclonal IgA kappa was detected on serum protein agarose electrophoresis followed by immunoblot. The level of IgA was 10.4 g/l, IgG 20 g/l and IgM 3.83 g/l. Bone marrow aspiration and a bone biopsy of the iliac crests disclosed signs of dysplasia but no plasmocyte infiltration. There was no detectable Bence-Jones protein in the urine. He was treated with three courses of VAD (doxorubicine 2.5 mg/m 2 by continuous i.v. infusion over 24 h for 4 consecutive days, vincristine 0.4 mg/day by continuous i.v. infusion over 24 h for 4 consecutive days and dexamethasone 40 mg p.o. on days 1-4, 9-12 and 17-20). Antiretroviral treatment was discontinued because of signs of neuropathy. On evaluation in November 1996 the monoclonal protein was no longer detectable in the serum. The level of IgA was 3.5 g/l. Bone marrow biopsy was negative. The bone lesions were stable on X-ray survey. The patient's recovery was complicated by Staphylococcus aureus septicemia originating from the central venous catheter, Clostridium difficile colitis, disseminated CMV infection with pneumonia, gastric ulcers and chorioretinitis, labial and anal herpetic lesions and an inguinal Herpes zoster infection.
Antiretroviral therapy was restarted in December 1996. Viral load was high (more than 250 000 copies RNA/ml) and the CD4 + count lwas ower than 50/mm 3 ; stavudine (D4T: 40 mg twice daily), lamivudine (3TC: 150 mg twice daily) and indinavir (800 mg three times daily) were given in combination. Cotrimoxazole prophylaxis was maintained.
In February 1997, the patient felt well. His viral load was Ͻ400 copies RNA/ml. After mobilization with G-CSF (filgrastim, Amgen, Thousand Oaks, CA, USA) 10 g/kg s.c. daily for 4 days, peripheral blood stem cells were harvested by cytapheresis and 8.3 × 10 6 CD34/kg were collected. Of these, 4.9 × 10 6 were used for CD34 + selection and 2.1 × 10 6 purified CD34 + cells were obtained with a purity of 81% (Isolex 300isystem: a gift from Baxter, Brussels, Belgium).
In April 1997, a new bone lesion appeared on the left ischium. Two monoclonal antibodies (one IgA and one IgG) and a kappa light chain were detected by serum IEP. The level of IgA was 2.8 g/l, IgG 7.6 g/l and IgM 0.33 g/l. Intensification with high-dose melphalan (200 mg/m 2 ) was started. Antiretroviral therapy and cotrimoxazole were continued. Ganciclovir and fluconazole were added. In order to avoid reinfusion of a large number of cells potentially infected with HIV, purified CD34
+ cells (2.1 × 10 6 cells/kg) were transfused. The patient received G-CSF 5 g/kg and the aplasia recovered 10 days later. The HIV viral load remained undetectable. CD4 + count remained low and never increased above 75/mm 3 . In August 1997, a relapse of both systemic and ocular CMV infection occurred requiring hospitalization for treatment with ganciclovir. After completion of therapy, the patient was able to resume work with maintenance oral ganciclovir and monthly i.v. immunoglobulin (400 mg/kg) infusions.
In April 1998, he was readmitted because of pneumococcal pneumonia with septicemia. Creatinine and calcium values were normal. A monoclonal IgA kappa was detected on serum protein agarose electrophoresis followed by immunoblot. IgA level was 1.24 g/l. He complained of lower back pain. Systematic X-ray of the skeleton disclosed lytic lesions in the left ischium, the proximal femoral diaphysis and three ribs. NMR of the spine disclosed tumoral lesions infiltrating the left ischial tuberosity, the second and fifth lumbar vertebra, and a paravertebral mass at the level of the 11 th and 12 th dorsal vertebrae invading paravertebral muscles. Pathological examination of bone biopsy material confirmed relapse of the multiple myeloma. The patient decided not to restart any antineoplastic therapy and returned home for palliative care. He died in May 1998, 21 months after diagnosis of the malignancy.
Discussion
Multiple myeloma occurs rarely in HIV carriers. However, some recent series have disclosed that the incidence of myeloma is increased in HIV-positive patients when compared with cohort-and registry-matching studies of HIV and cancer. [3] [4] [5] Multiple myeloma acquires special clinical characteristics in patients infected by HIV. They are much younger at the time of diagnosis (mean age of 35 patients reported in the literature: 42 years) when compared a the mean age at diagnosis in the general population, of between 60 and 70 years. 6 When HIV-positive patients with myeloma are compared with the general population, they also show an atypical clinical evolution, with a greater frequency of solitary plasmacytomas, less evidence of a monoclonal plasma component, greater aggressiveness of the neoplastic process or presentation as plasma cell leukemia. [7] [8] [9] Often, the course of the disease is very rapid with a short overall survival after diagnosis, especially in the first cases reported. Unfortunately, clinical data are often very scanty and do not allow evaluation of therapy, disease-free survival or overall survival. Radiotherapy has been used to treat isolated plasmacytomas.
Since myeloma is usually a disseminated disease at presentation, chemotherapy is the mainstay of treatment. This therapy is disappointing because the median survival varies from 24 to 32 months. 10 The French IFM90 trial comparing conventional chemotherapy with autologous bone marrow transplantation in previously untreated HIV-negative patients showed that both event-free survival and overall survival were improved by the use of autologous bone marrow transplantation. 11 To our knowledge, this therapy has never been used in HIV-positive patients with multiple myeloma. Our patient underwent this procedure without any major toxicity except for a reactivation of CMV disease. In retrospect, we should have attempted to continue antiretroviral therapy during the three courses of VAD; this could have improved the clinical course. Interestingly, the bone marrow signs of dysplasia did not influence the duration of aplasia. We and others have demonstrated that collection and grafting of peripheral blood stem cells is feasible in HIV-1-positive patients. [12] [13] [14] The immunological improvement that results from current antiretroviral therapy makes the risk of myeloablative chemotherapy fairly similar to that in HIV-1-negative patients. 12, 13 These data suggest that high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation might be an appropriate approach for selected HIV-positive patients with multiple myeloma receiving highly active antiretroviral therapy.
